Opinion on Pharmaceuticals and Healthcare

Published within

« | ... | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Vernalis: Frovelan concerns a headache for shareholders

Published By Datamonitor
20 Sep 2001
CommentWire
CommentWire

Vernalis: revised R&D focus after Frova decision hits home

Vernalis's decision to undergo major restructuring is a direct result of the non-approval of the company's sNDA submission for Frova, for the treatment of menstrual migraine. A successful application had been anticipated to double the revenue potential of Frova.

Published By Datamonitor
22 Feb 2008
CommentWire
CommentWire

Verta/SciClone: new drug could limit TB spread

According to preliminary results, Russian pharma company Verta's new immune system enhancing drug may have a significant impact on TB contagion. Although the treatment regime is arduous, involving five daily injections, there could be a significant market for SCV-07 in locations where Directly Observed Treatment can be implemented.

Published By Datamonitor
01 Oct 2002
CommentWire
CommentWire

Vertex Pharmaceuticals: strong evidence for VX-770 as a potential novel treatment method

Vertex Pharmaceuticals' novel cystic fibrosis treatment VX-770 has demonstrated strong efficacy in a Phase III trial, meeting the primary endpoint and key secondary endpoints. VX-770 targets the underlying cause of the disease, and, if approved, would offer a novel treatment approach.

Published By Datamonitor
25 Feb 2011
CommentWire
CommentWire

Vertex: dipping into the non-responders pool

Vertex has unveiled encouraging results from a phase Ib trial evaluating VX-950 in hepatitis C. Although investors have reacted well to the news, sending the company's stock to a new 52-week high, the battle is by no means won as continued uncertainty regarding class-specific toxicity demands caution. Indeed, it may well be too early for Vertex to celebrate just yet.

Published By Datamonitor
04 Oct 2005
Expert View
Expert View

Vertex: next-generation hepatitis drugs within reach

Vertex has launched a major phase II clinical trial to test a new hepatitis C drug candidate, with a second trial scheduled to begin in June. This is a significant advance in the development of much-needed treatments for hepatitis C. By drawing parallels with similar HIV treatments, Datamonitor's Morris Paterson outlines the pitfalls and prospects for this new drug.

Published By Datamonitor
24 May 2006
CommentWire
CommentWire

Vertex: Positive results for cystic fibrosis drug

Vertex has completed a Phase II trial of a small-molecule oral drug, VX-770, which targets the basic defect that occurs in cystic fibrosis (CF). The trial has only been performed in 20 patients from a small, genetically distinct subset of the CF population. However, the results are encouraging and indicate an alternative approach to traditional reactive management of CF.

Published By Datamonitor
28 Mar 2008
CommentWire
CommentWire

Vical: modified Leuvectin trials could do better

Published By Datamonitor
23 Apr 2001
CommentWire
CommentWire

Vicuron: dalbavancin in phase III trials

A phase III comparator trial for Vicuron's [VERS] dalbavancin has been initiated for the treatment of skin infections involving resistant pathogens. The critical dosing advantages of dalbavancin may help Vicuron to overcome both its limited marketing capability and restrictions on the use of novel products.

Published By Datamonitor
04 Nov 2003
CommentWire
CommentWire

Video detailing: study results not as strong as they look

Published By Datamonitor
29 Aug 2001

« | ... | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | ... | » »|

No help is available.